HOME >> BIOLOGY >> NEWS
Study finds shifts in treatment trends prior to publication of study results

The oral presentation of data from a single study at a national scientific conference can have an important impact on patient treatment, even before study publication or Food and Drug Administration (FDA) approval, according to a study in the March 15 issue of the Journal of the National Cancer Institute.

Specifically, the authors found that use of the chemotherapy drugs called taxanes increased after the May 1998 annual meeting of the American Society of Clinical Oncology (ASCO) where preliminary data were presented suggesting that use of taxanes as adjuvant therapy could improve survival in women with lymph node-positive breast cancer.

Results from the Cancer and Leukemia Group B (CALGB) Study 9344 suggested that adjuvant treatment with the taxane drug paclitaxel is associated with improved survival in women with lymph node-positive breast cancer. The results were first presented at the 1998 ASCO meeting. Although paclitaxel had been approved by the FDA in 1994 for the treatment of women with metastatic breast cancer, FDA approval for this new use of paclitaxel for women with node-positive breast cancer did not come until October 1999. A final report of CALGB Study 9344 was published in 2003. However, the preliminary results of the study presented in May 1998 were highlighted in news stories published in numerous major media outlets, including the New York Times, Wall Street Journal, and U.S. News and World Report.

To investigate the impact of the meeting presentation on practice patterns, Sharon H. Giordano, M.D., at the University of Texas M.D. Anderson Cancer Center, and colleagues studied chemotherapy use in 3341 women older than age 65, identified in the Surveillance, Epidemiology, and End Results-Medicare database, who were diagnosed with stage I-III breast cancer between 1994 and 1999 and received adjuvant chemotherapy within 1 year of diagnosis. The authors examined the use of taxanes among these women.
'"/>

Contact: Ariel Whitworth
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
14-Mar-2006


Page: 1 2 3

Related biology news :

1. Study begins to reveal clues to the cause and progression of sepsis
2. Study finds gender differences in renal and other genes contributing to blood pressure
3. Study suggests estrogen deficiency can lead to obesity-induced high blood pressure after menopause
4. Study: Sticking to the sand might not be such good, clean fun for beachgoers
5. Study points to new way to predict death risk from torn aorta
6. Study identifies new gene therapy tools for inherited blindness
7. Study finds contaminated water reaching Floridas offshore keys
8. Study sheds light on why humans walk on two legs
9. Study explains how pathogens evolve to escape detection
10. Study finds hereditary link to premenstrual depression
11. Study identifies energy efficiency as reason for evolution of upright walking

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/2/2020)... ... July 01, 2020 , ... ... 1a findings of Neihulizumab, a biologic for the treatment of steroid-refractory acute graft-versus-host ... by hemato-oncologist Dr. Paul J Martin of the Fred Hutchinson Cancer Research Center, ...
(Date:7/1/2020)... Calif. (PRWEB) , ... July 01, 2020 , ... ... on building awareness and solutions for glioblastoma—the most common and aggressive adult brain ... Lisa Haile, JD, PhD. Senior Fellows are charged with supporting the organization’s initiatives ...
(Date:6/25/2020)... , ... June 24, 2020 , ... ... enterprise software and software-driven clinical data services that accelerate drug development, is collaborating ... selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is the ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... 2020 , ... R3 Stem Cell International is now offering patients the opportunity ... cells total, patients may choose which extremities they would like treated. , Several studies ... Disord. 2016). At R3 International, umbilical cord tissue is obtained from a lab with ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... the leading global provider of advanced delivery technologies, development, and manufacturing solutions for ... they have entered into a strategic partnership whereby Catalent will provide support for ...
(Date:7/22/2020)... ... July 22, 2020 , ... Join experts from ... Sr. Manager Regulatory Solutions, in a one hour live webinar on Thursday, ... body in China for drugs and medical devices. Specifically, for medical devices, the NMPA ...
(Date:7/18/2020)... ... , ... dicentra , a leading Contract Research Organization ... pleased to announce that Charles Galea has joined its clinical trials division as ... accomplished and results-driven sales executive with over 10 years of expertise in business ...
Breaking Biology Technology:
Cached News: